Evotec SE Half-Year Interim Report 2026

Evotec SE reported a decrease in group revenues by 19.2% to €300.1 million for the first half of 2026, compared to €371.2 million in the same period of the previous year. This decline was primarily attributed to challenging market conditions and revenue timing effects, despite positive commercial execution. The Discovery & Preclinical Development (D&PD) segment saw a 15.2% decrease in revenue, while Just – Evotec Biologics (JEB) revenue decreased by 29.3%, largely due to a license sale in the prior year. Adjusted Group EBITDA turned to a loss of €42.7 million from a loss of €1.9 million in the prior year. The company updated its FY2026 outlook, expecting group revenues between €570-610 million and an adjusted EBITDA loss of €70-105 million. Key developments during the period include the launch of J.TRAIN by JEB, advancements in drug discovery alliances, and strategic initiatives under "Project Horizon" aimed at accelerating growth and enhancing value creation, which also resulted in significant reorganization costs.